New York-based TG Therapeutics announced positive topline results from two global Phase III clinical trials, ULTIMATE I and II, of ublituximab in relapsing forms of multiple sclerosis (RMS).
Gilead Sciences Inc. bolstered the company’s capabilities in treating liver diseases with a €1.15 billion ($1.4 billion) cash acquisition of Germany-based Myr GmbH, which is focused on developing therapies for the treatment of chronic hepatitis delta virus (HDV), the most severe form of viral hepatitis.
Boehringer Ingelheim is paying 1.18 billion euros ($1.5 billion) for Swiss-based NBE Therapeutics as the German drugmaker is adding pipeline candidates including a drug in early trials against triple-negative breast cancer and lung cancer.
An historic alliance of life sciences and healthcare organizations seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
Roche is partnering with Moderna to include a Covid-19 antibody test in the mRNA specialist’s ongoing vaccine trials, the Swiss drugmaker said, potentially demonstrating if the vaccine is working.
Companies and industry groups lobbying to get their U.S. workers to the front of the line for COVID vaccination are running into a patchwork of state plans and confusion over who is essential, and who is not.
Remix Therapeutics officially launched with $81 million in financing, with the funds to be used to support the development of the company’s REMaster technology platform while advancing a pipeline of RNA processing targeted therapeutics.
European life sciences venture capital firm Forbion announced a fifth fund of €460 million ($545 million) to invest in life sciences companies.
Pfizer Inc. cleared the next hurdle in the race to get the company’s Covid-19 vaccine approved for emergency use after the U.S. Food and Drug Administration released documents that raised no new issues about its safety or efficacy.
The U.S. Food and Drug Administration requested ALX Oncology complete a standard safety study, which amounts to a partial clinical hold on a Phase II study pairing the company’s CD47 inhibitor ALX148 with Merck’s Keytruda in Head & Neck Squamous Cell Carcinoma (HNSCC).
